What Happened?

Shares of clinical research company Fortrea Holdings (NASDAQ: FTRE) fell 4.5% in the afternoon session after Mizuho lowered its price target on the shares ahead of the company's second-quarter earnings report. The investment bank reduced its price target, which is an analyst's projection of a stock's future price, to $7 from a previous $8, while keeping a "Neutral" rating on the stock. This adjustment signals a slightly more cautious outlook from the analyst on the company's valuation. The move comes as the contract research organization continues to navigate challenges. Mizuho noted that while the outlook for the hospital sector appears clear, managed care companies are still struggling with cost trends.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Fortrea? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Fortrea’s shares are extremely volatile and have had 52 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Fortrea is down 72.9% since the beginning of the year, and at $5.05 per share, it is trading 81.9% below its 52-week high of $27.92 from July 2024. Investors who bought $1,000 worth of Fortrea’s shares at the IPO in June 2023 would now be looking at an investment worth $167.70.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.